Skip to main content

Advertisement

Table 1 Baseline characteristics, types of β-lactams, and severity of patients with neutropenic pneumonia

From: Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens

Variables β-lactam group (n = 72) Combination group (n = 93) P-value
Demographic data
 Age, years 61 ± 11 62 ± 10 0.296
 Male sex 59 (81.9%) 59 (63.4%) 0.009
 Smoking history 29 (40.3%) 27 (29.0%) 0.130
Comorbid conditions
 Hypertension 14 (19.4%) 28 (30.1%) 0.119
 Diabetes mellitus 5 (6.9%) 12 (12.9%) 0.212
 Cardiovascular diseases 5 (6.9%) 2 (2.2%) 0.130
 Chronic lung diseases 3 (4.2%) 6 (6.5%) 0.733
 Chronic liver diseases 3 (4.2%) 3 (3.2%) 1.000
 Chronic renal diseases 0 (0.0%) 6 (6.5%) 0.036
Types of β-lactams
 Cefepime 40 (55.6%) 64 (68.8%) 0.080
 Ceftazidimea 20 (27.8%) 2 (2.2%) <  0.001
 Piperacillin/tazobactam 6 (8.3%) 21 (22.6%) 0.014
 Carbapenem 6 (8.3%) 6 (6.5%) 0.644
 Duration of antibiotic administration, days 12.4 (8.9–16.2) 11.7 (9.1–14.4) 0.646
Severity variables
 Presence of bacteremia 16 (22.0%) 12 (12.9%) 0.114
 Duration of neutropenia, days 1.5 (0.9–3.1) 1.4 (1.0–2.9) 0.773
 CRP, mg/dL 15.9 (6.5–24.0) 17.0 (6.4–25.9) 0.669
 CURB-65 1 (0–2) 1 (0–2) 0.898
 MASCC risk index 16 (13–18) 16 (16–21) 0.059
  1. Data are expressed as number (%) of patients, mean ± SD, or median (IQR)
  2. aCeftazidime was administered with tobramycin for an initial 3–5 days
  3. Abbreviations: CRP C-reactive protein, MASCC Multinational Association for Supportive Care in Cancer, SD Standard deviation, IQR interquartile range